1887

Journal of General Virology header logo

Volume 97, Issue 9

Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines Free

Abstract

Recombinant measles virus (rMV) vectors expressing heterologous viral membrane protein antigens are potentially useful as vaccines. Genes encoding the mumps virus haemagglutinin-neuraminidase (MuV-HN), the influenza virus haemagglutinin (Flu-HA) or the respiratory syncytial virus fusion (RSV-F) proteins were inserted into the genome of a live attenuated vaccine strain of measles virus. Additionally, in this case rMV with the MuV-HN or the influenza HA inserts, chimeric constructs were created that harboured the measles virus native haemagglutinin or fusion protein cytoplasmic domains. In all three cases, sucrose-gradient purified preparations of rMV were found to have incorporated the heterologous viral membrane protein on the viral membrane. The possible utility of rMV expressing RSV-F (rMV.RSV-F) as a vaccine was tested in a cotton rat challenge model. Vaccination with rMV.RSV-F efficiently induced neutralizing antibodies against RSV and protected animals from infection with RSV in the lungs.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): hemagglutinin , influenza , mumps , recombinant measles and respiratory syncitial virus
© 2016 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000523
2016-09-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/9/2117.html?itemId=/content/journal/jgv/10.1099/jgv.0.000523&mimeType=html&fmt=ahah

References

  1. Albrecht P., Herrmann K., Burns G. R. 1981; Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 3:251–260[PubMed] [CrossRef]
     [Google Scholar]
  2. Bolton D. L., Santra S., Swett-Tapia C., Custers J., Song K., Balachandran H., Mach L., Naim H., Kozlowski P. A. et al. 2012; Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates. Vaccine 30:5991–5998 [View Article][PubMed]
     [Google Scholar]
  3. Boukhvalova M. S., Prince G. A., Blanco J. C. 2009; The cotton rat model of respiratory viral infections. Biologicals 37:152–159 [View Article][PubMed]
     [Google Scholar]
  4. Brandenburg B., Koudstaal W., Goudsmit J., Klaren V., Tang C., Bujny M. V., Korse H. J., Kwaks T., Otterstrom J. J. et al. 2013; Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One 8:e80034 [View Article][PubMed]
     [Google Scholar]
  5. Cantarella G., Liniger M., Zuniga A., Schiller J. T., Billeter M., Naim H. Y., Glueck R. 2009; Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 27:3385–3390 [View Article][PubMed]
     [Google Scholar]
  6. Guerbois M., Moris A., Combredet C., Najburg V., Ruffié C., Février M., Cayet N., Brandler S., Schwartz O. et al. 2009; Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 388:191–203 [View Article][PubMed]
     [Google Scholar]
  7. Kim E., Okada K., Beeler J. A., Crim R. L., Piedra P. A., Gilbert B. E., Gambotto A. 2014; Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J Virol 88:5100–5108 [View Article][PubMed]
     [Google Scholar]
  8. Li M., Schmitt P. T., Li Z., McCrory T. S., He B., Schmitt A. P. 2009; Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles. J Virol 83:7261–7272 [View Article][PubMed]
     [Google Scholar]
  9. Liniger M., Zuniga A., Morin T. N., Combardiere B., Marty R., Wiegand M., Ilter O., Knuchel M., Naim H. Y. 2009; Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 27:3299–3305 [View Article][PubMed]
     [Google Scholar]
  10. McLean H. Q., Fiebelkorn A. P., Temte J. L., Wallace G. S. Centers for Disease Control and Prevention 2013; Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 62:1–34[PubMed]
     [Google Scholar]
  11. Mok H., Cheng X., Xu Q., Zengel J. R., Parhy B., Zhao J., Wang C. K., Jin H. 2012; Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein-Barr virus glycoprotein gp350. Open Virol J 6:12–22 [View Article][PubMed]
     [Google Scholar]
  12. Mourez T., Mesel-Lemoine M., Combredet C., Najburg V., Cayet N., Tangy F. 2011; A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells. Virology 419:117–125 [View Article][PubMed]
     [Google Scholar]
  13. Parks C. L., Lerch R. A., Walpita P., Sidhu M. S., Udem S. A. 1999; Enhanced measles virus cDNA rescue and gene expression after heat shock. J Virol 73:3560–3566[PubMed]
     [Google Scholar]
  14. Prince G. A., Jenson A. B., Horswood R. L., Camargo E., Chanock R. M. 1978; The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 93:771–791[PubMed]
     [Google Scholar]
  15. Prince G. A., Potash L., Horswood R. L., Camargo E., Suffin S. C., Johnson R. A., Chanock R. M. 1979; Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats. Infect Immun 23:723–728[PubMed]
     [Google Scholar]
  16. Prince G. A., Horswood R. L., Chanock R. M. 1985; Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 55:517–520[PubMed]
     [Google Scholar]
  17. Radecke F., Spielhofer P., Schneider H., Kaelin K., Huber M., Dötsch C., Christiansen G., Billeter M. A. 1995; Rescue of measles viruses from cloned DNA. EMBO J 14:5773–5784[PubMed]
     [Google Scholar]
  18. Ramsauer K., Schwameis M., Firbas C., Müllner M., Putnak R. J., Thomas S. J., Desprès P., Tauber E., Jilma B. et al. 2015; Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15:519–527 [View Article][PubMed]
     [Google Scholar]
  19. Rennick L. J., de Vries R. D., Carsillo T. J., Lemon K., van Amerongen G., Ludlow M., Nguyen D. T., Yüksel S., Verburgh R. J. et al. 2015; Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates. J Virol 89:2192–2200 [View Article][PubMed]
     [Google Scholar]
  20. Sawada A., Komase K., Nakayama T. 2011; AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats. Vaccine 29:1481–1490 [View Article][PubMed]
     [Google Scholar]
  21. Schwarzer S., Reibel S., Lang A. B., Struck M. M., Finkel B., Gerike E., Tischer A., Gassner M., Glück R. et al. 1998; Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine 16:298–304 [View Article][PubMed]
     [Google Scholar]
  22. Singh M., Cattaneo R., Billeter M. A. 1999; A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 73:4823–4828[PubMed]
     [Google Scholar]
  23. Spielhofer P., Bächi T., Fehr T., Christiansen G., Cattaneo R., Kaelin K., Billeter M. A., Naim H. Y. 1998; Chimeric measles viruses with a foreign envelope. J Virol 72:2150–2159[PubMed]
     [Google Scholar]
  24. Storch G. A. 1998; Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics 102:648–651 [View Article][PubMed]
     [Google Scholar]
  25. Tangy F., Naim H. Y. 2005; Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol 18:317–326 [View Article][PubMed]
     [Google Scholar]
  26. Throsby M., van den Brink E., Jongeneelen M., Poon L. L., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E. et al. 2008; Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3:e3942 [View Article][PubMed]
     [Google Scholar]
  27. Wang Z., Hangartner L., Cornu T. I., Martin L. R., Zuniga A., Billeter M. A., Naim H. Y. 2001; Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 19:2329–2336 [View Article][PubMed]
     [Google Scholar]
  28. Welliver T. P., Garofalo R. P., Hosakote Y., Hintz K. H., Avendano L., Sanchez K., Velozo L., Jafri H., Chavez-Bueno S. et al. 2007; Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195:1126–1136 [View Article][PubMed]
     [Google Scholar]
  29. Widjojoatmodjo M. N., Bogaert L., Meek B., Zahn R., Vellinga J., Custers J., Serroyen J., Radošević K., Schuitemaker H. 2015; Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. Vaccine 33:5406–5414 [View Article][PubMed]
     [Google Scholar]
  30. Wu H., Pfarr D. S., Johnson S., Brewah Y. A., Woods R. M., Patel N. K., White W. I., Young J. F., Kiener P. A. 2007; Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 368:652–665 [View Article][PubMed]
     [Google Scholar]
  31. Yamaji Y., Nakayama T. 2014; Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats. Vaccine 32:4529–4536 [View Article][PubMed]
     [Google Scholar]
  32. Zuniga A., Liniger M., Morin T. N., Marty R. R., Wiegand M., Ilter O., Weibel S., Billeter M. A., Knuchel M. C. et al. 2013; Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Hum Vaccin Immunother 9:607–613 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000523
Loading
Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines
J. Gen. Virol. 97, 2117 (2016); https://doi.org/10.1099/jgv.0.000523
/content/journal/jgv/10.1099/jgv.0.000523
/content/journal/jgv/10.1099/jgv.0.000523
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error